The value of anti-Mullerian hormone in the management of polycystic ovary syndrome in adolescents

Asanidze, Elene; Kristesashvili, J.; Pkhaladze, Lali; Khomasuridze, Archil

doi:10.1080/09513590.2019.1616689

Cited by 19 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The functions of AMH beyond reproduction have been investigated recently, but no strong conclusions could be drawn regarding the relationship between AMH and metabolic health in PCOS patients due to the heterogeneous nature of such populations and the lack of adjustment for possible confounders of metabolism. In healthy adult women with a regular menstrual cycle, lower AMH levels have been found to be associated with increased risk of metabolic disorders, although this correlation is negative in adolescents [ 12 ]. There is also some evidence indicating that lower AMH level is a metabolic risk factor, but debates on the correlation between AMH and obesity emphasize the complexity of the physiopathology of the PCOS population [ 6 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

AMH Is a Good Predictor of Metabolic Risk in Women with PCOS: A Cross-Sectional Study

Lin

et al. 2021

International Journal of Endocrinology

View full text Add to dashboard Cite

Objective. The relationship between metabolic risk and ovarian function is ambiguous. This retrospective study analyzed the medical records of 461 PCOS patients collected between January 2019 and June 2020 to investigate the relationship between serum anti-Müllerian hormone (AMH) and parameters of metabolic risk in the population with polycystic ovary syndrome (PCOS). Methods. A total of 461 PCOS patients aged 20–40 years were included and stratified into four groups according to the AMH level. The association between AMH and the parameters related to metabolic risk in these groups was compared, and the discrepancies were further explored. Binary logistic regression was performed to examine the risk factors of HOMA-IR. The values of AMH that best predicted the risk of HOMA-IR were also analyzed by ROC curves. Results. AMH was negatively associated with HOMA-IR (odds ratio (OR) −0.279, 95% confidence interval (CI) −0.36 to −0.20), fasting insulin (OR −0.282, 95% CI −0.36 to −0.20), 1-hour postprandial insulin (OR −0.184, 95% CI −0.28 to −0.11), 2-hour postprandial insulin (−0.180, 95%CI −0.28 to −0.11), 3-hour postprandial insulin (OR −0.198, 95% CI –0.30 to −0.13), waist-hip ratio (OR −0.235, 95% CI −0.31 to −0.14), and body mass index (OR −0.350, 95% CI −0.43 to −0.27). There was no statistically significant relationship between blood pressure, serum glucose profile, or lipid levels and AMH. Binary logistic regression showed that AMH protected against the occurrence of PCOS patients (OR: 0.835, 0.776, and 0.898). For the prediction of HOMA-IR, AMH had an AUC-ROC of 0.704 (95% CI 0.652–0.755) with a cutoff value of 7.81 mmol/L, a sensitivity of 70.3%, and a specificity of 70.1%. Conclusions. Higher AMH levels were significantly associated with a lower insulin profile and might be a useful predictor for HOMA-IR in PCOS patients.

show abstract

Section: Introductionmentioning

confidence: 99%

AMH Is a Good Predictor of Metabolic Risk in Women with PCOS: A Cross-Sectional Study

Lin

et al. 2021

International Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…18 Nevertheless, Dursun et al 21 demonstrated that treatment with COC with or without metformin reduced AMH levels, independently of hyperandrogenism. Similarly, Asanidze et al 23 showed AMH levels were reduced after treatment with combined oral contraceptives (COCs) or with COCs plus inositols. Hence, AMH might be a good marker for monitorization.…”

Section: Diagnosismentioning

confidence: 90%

“…Hence, AMH might be a good marker for monitorization. 21,23 Finally, moderate to severe comedonal acne (that is, ! 10 facial lesions) or moderate to severe persistent inflammatory acne unresponsive to topical therapy is uncommon even within this age group and should prompt biochemical evaluation for hyperandrogenemia prior to medical treatment.…”

Section: Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Polycystic Ovary Syndrome in Adolescence: Challenges in Diagnosis and Management

Manique

Póvoa

2022

Rev Bras Ginecol Obstet

View full text Add to dashboard Cite

Diagnosing polycystic ovary syndrome (PCOS) during adolescence is challenging since normal pubertal development overlap typical features of this syndrome. The authors aim to summarize the existing evidence concerning PCOS in adolescence, particularly its diagnostic criteria and therapeutic options. A search throughout medical databases such as PubMed and MedScape was performed. Diagnostic criteria include irregular menstrual cycles according to time postmenarche and evidence of clinical hyperandrogenism and/or biochemical hyperandrogenism, provided other causes have been excluded. Polycystic ovarian morphology ought not to be used as a diagnostic criterion. Treatment should target manifestations and/or comorbidities, even in the absence of a definite diagnosis. Lifestyle interventions are the first-line treatment. Combined oral contraceptives, metformin or antiandrogens may also be considered as adjuvants. Screening for PCOS in adolescence is crucial as it allows an early intervention on the symptoms and comorbidities presented leading to better long-term reproductive and metabolic outcomes.

show abstract

“…Benzer şekilde serum AMH değerlerini düşürdüğünü belirten çalışmaların yanı sıra herhangi bir etkisinin olmadığını saptayan çalışmalar da mevcuttur. 36,[44][45][46][47] MYO ve/veya DCI tedavisinin PKOS hastalarında AMH üzerine etkisi ile ilgili ağırlıklı görüş olumlu yönde görülse de konunun netleştirilmesi için yeni araştırmalara ihtiyaç olduğu açıktır.…”

Section: Anti̇mülleri̇an Hormonunclassified

The Role of Myo-Inositol in the Treatment of Polycystic Over Syndrome

Özay¹,

Özay²,

Gülekli³

2019

TJRMS

View full text Add to dashboard Cite

Polikistik over sendromu, üreme çağında en sık görülen endokrinolojik hastalıktır ve anovulasyonun en sık nedenidir. İnsülin direncinin PKOS etyopatogenezinde rol oynayabileceği ve insülin duyarlılaştırıcıların PKOS hastalarında başarı ile kullanımları, yeni araştırmalara yol gösterici olmaktadır. B6 vitamininin steroizomeri olan myoinositol üzerine son zamanlarda çok sayıda çalışma yapılmaktadır ve bu çalışmaların sonuçlarında genel izlenim myoinositol kullanımının olumlu olduğu yönündedir.Anah tar Ke li me ler: Polikistik over sendromu; myoinositol; insülin direnci; antimüllerian hormon; ovulasyon indüksiyonu, ovarian stromal doppler ABS TRACTPolycystic ovary syndrome is the most common endocrinological disease in the reproductive age and most common cause of anovulation. Insulin resistance may play a role in the etiopathogenesis of PCOS and the successful use of insulin sensitizers in PCOS patients is giving new insights for the treatment for new studies. There have been many studies on myoinositol, the steroisomer of vitamin B6, and the general impression of these studies is that myoinositol use is positive.

show abstract

The value of anti-Mullerian hormone in the management of polycystic ovary syndrome in adolescents

Cited by 19 publications

References 26 publications

AMH Is a Good Predictor of Metabolic Risk in Women with PCOS: A Cross-Sectional Study

AMH Is a Good Predictor of Metabolic Risk in Women with PCOS: A Cross-Sectional Study

Polycystic Ovary Syndrome in Adolescence: Challenges in Diagnosis and Management

The Role of Myo-Inositol in the Treatment of Polycystic Over Syndrome

Contact Info

Product

Resources

About